user

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation

被引：0
|
作者：
Weisser, Martin [1 ,2 ]
Tischer, Johanna [1 ,2 ]
Schnittger, Susanne [3 ]
Schoch, Claudia [3 ]
Ledderose, Georg [1 ,2 ]
Kolb, Hans Jochem [1 ,2 ]
机构：
[1] Univ Munich, Hematopoet Cell Transplantat, Dept Med 3, Klinikum Grosshadern,Ludwig Maximilian Univ Munic, Munich, Germany
[2] GSF Natl Res Ctr Environm & Hlth, Munich, Germany
[3] Munich Leukemia Lab, Munich, Germany
来源：
HAEMATOLOGICA | 2006年 / 91卷 / 05期
关键词：
donor lymphocyte infusion; imatinib; chronic myelogenous leukemia; allogeneic stem cell transplantation; relapse;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions. The outcome of CML patients transplanted at our center who had received only imatinib for relapse after HSCT was compared with that of patients treated with donor lymphocyte infusions (DLI). Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively). These data suggest that imatinib alone probably does not cure relapse after HSCT.
引用
下载
收藏
页码：663 / 666
页数：4
相关论文
共 50 条
  • [31] Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias
    A Shimoni
    N Kröger
    A R Zander
    J M Rowe
    I Hardan
    A Avigdor
    M Yeshurun
    I Ben-Bassat
    A Nagler
    Leukemia, 2003, 17 : 290 - 297
  • [32] Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
    Gurman, Gunhan
    Seval, Guldane Cengiz
    Bozdag, Sinem Civriz
    Toprak, Selami Kocak
    Yuksel, Meltem Kurt
    Topcuoglu, Pervin
    Arslan, Onder
    Ozcan, Muhit
    Demirer, Taner
    Ilhan, Osman
    Beksac, Meral
    Akan, Hamdi
    BLOOD, 2018, 132
  • [33] Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Giralt, S
    Rios, MB
    Shan, J
    Giles, F
    Thomas, D
    Faderl, S
    de Lima, M
    Arlinghaus, RB
    Garcia-Manero, G
    Issa, JP
    Resta, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [34] EFFICACY OF RITUXIMAB AND DONOR LYMPHOCYTE INFUSIONS AS SALVAGE TREATMENT IN LYMPHOMA PATIENTS RELAPSED AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION
    Spina, F.
    Farina, L.
    Montefusco, V.
    Carniti, C.
    Piva, S.
    Morelli, M.
    Corradini, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 61 - 61
  • [35] MOLECULAR REMISSION OCCURRING AFTER DONOR LEUKOCYTE INFUSIONS FOR THE TREATMENT OF RELAPSED CHRONIC MYELOGENOUS LEUKEMIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    DROBYSKI, WR
    ROTH, MS
    THIBODEAU, SN
    GOTTSCHALL, JL
    BONE MARROW TRANSPLANTATION, 1992, 10 (03) : 301 - 304
  • [36] Sequential treatment with reduced intensity allogeneic stem cell transplantation and imatinib for chronic myelogenous leukemia
    Champlin, R
    Ghosh, S
    McCormick, G
    Andersson, B
    de Lima, M
    Anderlini, P
    Qazilbash, M
    Giralt, S
    Cortes, J
    BLOOD, 2004, 104 (11) : 232A - 232A
  • [37] Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: A preliminary assessment
    Simon, William
    Segel, George B.
    Lichtman, Marshall A.
    BLOOD CELLS MOLECULES AND DISEASES, 2006, 37 (02) : 116 - 124
  • [38] Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.
    Pavlu, Jiri
    Klammer, Matthias
    Gabriel, Ian
    Szydlo, Richard
    Olavarria, Eduardo
    Milojkovic, Dragana
    Kew, Andrea
    Rezvani, Katy
    Dazzi, Francesco
    Marin, David
    Goldman, John
    Apperley, Jane
    BLOOD, 2008, 112 (11) : 357 - 357
  • [39] A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation
    Shanavas, Mohamed
    Messner, Hans A.
    Kamel-Reid, Suzanne
    Atenafu, Eshetu G.
    Gupta, Vikas
    Kuruvilla, John
    Kim, Dennis Dong Hwan
    Uhm, Jieun
    Lambie, Anna
    Ellis, Laura
    Lipton, Jeffrey H.
    BLOOD, 2013, 122 (21)
  • [40] Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: A molecular analysis
    Palandri, F
    Martinelli, G
    Amabile, M
    Bonifazi, F
    Bandini, G
    Benedetti, F
    Usala, E
    Angelucci, E
    Tiribelli, M
    Fanin, R
    Sorio, M
    Arpinati, M
    Testoni, N
    Falcioni, S
    Giannini, MB
    Poerio, A
    Soverini, S
    Pane, F
    Rosti, G
    Tura, S
    Baccarani, M
    BLOOD, 2004, 104 (11) : 247B - 247B
12345